Protocol summary
-
Study aim
-
Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, and frailty in older adults with mild cognitive impairment
-
Design
-
A clinical trial with control group, double-blind, randomized, parallel-group on 63 participants. Random Allocation Software was used for randomization.
-
Settings and conduct
-
Participants will be selected by simple random sampling from elderly care centers across Shiraz; after screening and confirming the disease, and if they meet the study entry criteria, the informed consent form will be completed. Participants will be placed in one of three groups: magnesium intervention, synbiotic, and placebo by a random block method. Outcomes will be evaluated at the beginning and end of the study. The duration of the intervention is 8 weeks. Also, in this study, participants and the researcher will be blinded.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria included: age 65 years and older, mild cognitive impairment, no severe renal/liver/pulmonary insufficiency, no uncontrolled diabetes, no severe neurological or psychiatric disorders, no adherence to special diets, no current use of medications that interact with magnesium. Exclusion criteria included changes in usual diet and medication, initiation of antibiotic therapy, occurrence of any side effects that stopped with discontinuation of the intervention, adherence of less than 80% and unwillingness to continue cooperation.
-
Intervention groups
-
Eligible people are placed in one of the following groups by random blocking method:
group1: taking a capsule containing 300 mg of elemental magnesium daily. Group 2: taking a synbiotic capsule daily. Group 3: taking a placebo
-
Main outcome variables
-
Cognitive function, quality of life, frailty
General information
-
Reason for update
-
1. Removal of serum hs-CRP measurement:
Given that the implementation and sample collection phases of the study coincided with a period of critical and unstable social conditions, including the war and its related consequences, regular participant follow-up and laboratory visits became challenging. This issue was particularly relevant given the clinical trial design of the study, which requires continuous and regular follow-up of participants. In addition, budgetary constraints contributed to this limitation. Therefore, measurement of high-sensitivity C-reactive protein (hs-CRP) was removed from the study. Accordingly, the study title, objectives, problem statement, methodology, assessment tools, and other relevant sections of the protocol were reviewed and revised.
2. Removal of the PASE questionnaire and use of the third section of the Fried Frailty Scale:
Since both the Physical Activity Scale for the Elderly (PASE) and the Fried Frailty Scale assess physical activity and have considerable overlap in terms of their content, the PASE questionnaire was removed from the study to reduce the assessment burden and facilitate greater cooperation among older participants. Therefore, participants’ physical activity levels will be assessed solely using the third section of the Fried Frailty Scale. Accordingly, the section describing the instrument used to assess physical activity was reviewed and revised.
3. Expansion of the study recruitment sites:
To increase the diversity of the study population and reduce the potential for selection bias associated with recruiting participants from a single site, the study recruitment setting was expanded from one elderly-related center to all elderly care centers across Shiraz. Accordingly, individuals will undergo screening at centers across the city, and those who meet the criteria will be referred to the Imam Reza (AS) Clinic. Accordingly, the sections describing the study setting and participant recruitment procedures were revised and updated.
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20250317065109N1
Registration date:
2025-04-02, 1404/01/13
Registration timing:
prospective
Last update:
2026-09-17, 1405/06/26
Update count:
1
-
Registration date
-
2025-04-02, 1404/01/13
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
-
Expected recruitment start date
-
2025-04-21, 1404/02/01
-
Expected recruitment end date
-
2025-09-22, 1404/06/31
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, and frailty in older adults with mild cognitive impairment
-
Public title
-
Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, and frailty
-
Purpose
-
Supportive
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Age 65 years and older
Suffering from mild cognitive impairment, based on the Mini-ACE cognitive function evaluation form
Ability and willingness to participate in the study
No smoking/alcohol and drug addiction
Absence of severe renal/hepatic/pulmonary insufficiency, uncontrolled diabetes, severe neurological or psychiatric disorders such as Bipolar disorder, Parkinson's disease, Dementia, unstable thyroid disease; Immune disorders such as HIV/AIDS
Not following specific diets (such as Ketogenic, Vegetarian, etc.)
No current use of medications that interact with magnesium, such as muscle relaxants, Penicillamine, Corticosteroids, Methyldopa, Magnesium-containing antacids, or other magnesium-containing products
Participants must have not taken antibiotics and probiotic, magnesium, and antioxidant supplements for at least 2 weeks prior to the start of the study
Exclusion criteria:
Changes in usual diet and medication
Starting antibiotic therapy
The occurrence of any side effects that stops when the intervention is discontinued.
Less than 80% adherence to supplement use
Unwillingness to continue cooperation
-
Age
-
From 65 years old
-
Gender
-
Both
-
Phase
-
N/A
-
Groups that have been masked
-
- Participant
- Investigator
- Outcome assessor
- Data analyser
-
Sample size
-
Target sample size:
63
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
Participants will be randomly assigned to three groups: magnesium intervention, synbiotic intervention, and control (A, B, C) based on the random blocking method using the Random Allocation Software with a ratio of 1:1:1.
This group assignment will be done by a person outside the study before the start of the design implementation process, and these sequences will be placed in sealed numbered envelopes by the same person in order to blind the researchers to the participant group by concealing the allocation.
After screening with a cognitive function assessment questionnaire and confirmation of mild cognitive impairment, participants will be referred to the research team. After completing the evaluations and the initial questionnaires, an envelope will be opened according to the established order, and the assigned intervention group will be determined for the participating individual.
This randomization and the groups will remain hidden from the researchers and participants until the statistical analysis is complete.
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
In the first phase of the study, the supplements and placebo are placed in capsules that are similar in color, size, and shape and are packaged. In this phase, the capsules are labeled with the Latin contract names A, B, and C. In the intervention phase, the random assignment sequence is also identified with the same names by a person outside the study.
Therefore, during the study, the participants and the researcher, who is in charge of carrying out the clinical phase, clinical evaluations, follow-up of laboratory tests, and data analysis, will be blinded to the assigned group and the intervention in each group.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2025-02-16, 1403/11/28
-
Ethics committee reference number
-
IR.SUMS.SCHEANUT.REC.1403.119
Health conditions studied
1
-
Description of health condition studied
-
Mild cognitive impairment
-
ICD-10 code
-
G31.84
-
ICD-10 code description
-
Mild cognitive impairment, so stated
Primary outcomes
1
-
Description
-
Cognitive function score in the Mini-Addenbrooke’s Cognitive Examination (M-ACE) questionnaire
-
Timepoint
-
Cognitive function assessment before the start of the intervention and 8 weeks later (end of the study)
-
Method of measurement
-
Mini-Addenbrooke’s Cognitive Examination (Mini-ACE) questionnaire
Secondary outcomes
1
-
Description
-
Quality of life score in the Older People's Quality of Life questionnaire (OPQOL-brief)
-
Timepoint
-
Quality of life assessment before the start of the intervention and 8 weeks later (end of the study)
-
Method of measurement
-
Older People's Quality of Life questionnaire-brief version (OPQOL-brief)
2
-
Description
-
Frailty score in the Frailty Syndrome Checklist 5-Items in Frail Older Adults in Iran (Fried's Five-Point Frailty Test)
-
Timepoint
-
Frailty assessment before the start of the intervention and 8 weeks later (end of the study)
-
Method of measurement
-
Frailty score in the Frailty Syndrome Checklist 5-Items in Frail Older Adults in Iran (Fried's Five-Point Frailty Test)
Intervention groups
1
-
Description
-
First intervention group: In this group, individuals will receive one capsule containing 300 mg of elemental magnesium (500 mg of magnesium in the form of magnesium oxide) daily for 8 weeks. Magnesium supplements will be prepared by Jalinous Pharmaceutical Company in the form of magnesium oxide powder and encapsulated by the Shiraz Faculty of Pharmacy.
-
Category
-
Treatment - Other
2
-
Description
-
Second intervention group: In this group, individuals will receive one synbiotic capsule daily for 8 weeks. The synbiotic supplement will be provided in capsule form by the Zist Takhmir Pharmaceutical Company (Familact®). This supplement contains 109 CFU of probiotics including Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium bifidum, Streptococcus thermophilus, and 74 mg of fructooligosaccharide in synbiotic form.
-
Category
-
Treatment - Other
3
-
Description
-
Control group: In this group, individuals will receive a placebo in capsule form that is similar in appearance to the intervention group for 8 weeks. Also, the placebo will be provided in capsule form by Zist Takhmir Pharmaceutical Company. The content of the placebo will be mostly maltodextrin and lactose monohydrate.
-
Category
-
Placebo
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Shiraz University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available